Phase I Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of Anti-CD30 Bispecific Antibody-armed Anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC) in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

This first-in-human trial will assess the safety, feasibility, and efficacy of an immunotherapy with a novel CD30 antibody conjugated to a CD3 antibody that is preloaded onto a patient's own T-cells, generating a CD30 bispecific antibody-armed, anti-CD3-activated, autologous T-cells (CD30 biAb-AATC).

Start Date01 Dec 2024

Sponsor / Collaborator

Medical College of Wisconsin

NCT06018129 / RecruitingPhase 1/2

A Phase 1/2a, Open-Label, Dose Escalation Trial of GEN3017 With Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma

The purpose of this trial is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of GEN3017 as a monotherapy in participants with relapsed or refractory (R/R) CD30-expressing lymphomas.
GEN3017 will be administered via subcutaneous injections.
All participants will receive active drug; no one will be given placebo.

Start Date21 Sep 2023

Sponsor / Collaborator

Genmab, Inc.

100 Clinical Results associated with CD3 x CD30

100 Translational Medicine associated with CD3 x CD30

0 Patents (Medical) associated with CD3 x CD30

964

Literatures (Medical) associated with CD3 x CD30

01 Nov 2024·The American Journal of Dermatopathology

Lymphomatoid Papulosis Type D in a Mestizo-Ancestry Man

Article

Author: Gómez, Nadia ; Villegas-González, Sofía Saraí ; Magaña, Mario

Abstract:Lymphomatoid papulosis (LyP) belongs to the CD30+ skin lymphoproliferative disorders; it is defined as a chronic, recurrent, self-healing eruption of papules and small nodules with the histopathologic features of a cutaneous T-cell lymphoma. It is classified according to histopathology into subtypes A to F and with chromosomal rearrangement 6p25.3. Type D is characterized by epidermotropism of atypical CD8+ and CD30+ lymphocytes, small to medium size, forming papules and nodules with erosion and necrosis, which represents a formidable challenge in the differential diagnosis with aggressive cutaneous cytotoxic lymphomas. We present the clinical case of a 22-year-old man with subacute dermatosis, who underwent a skin biopsy with a report of LyP. Immunohistochemistry showed negative CD4, CD5, granzyme-B markers and positive CD3, CD30, CD8, CD56, and (T-cell intracellular antigen 1) TIA-1 markers, concluding the diagnosis of type D LyP. The course of the disease is recurrent; however, the prognosis is good with a 10-year survival of 100%. We present the case of a mestizo-ancestry patient who developed a type-D LyP, and, to the best of our knowledge, there are no publications of type D LyP from Latin-American authors or about mestizo-ancestry (or hispanic) patients; therefore, we consider of relevance to inform about these findings.

01 Oct 2024·Journal of Oral and Maxillofacial Surgery

An Unusual Clinical Presentation of Traumatic Ulcerative Granuloma With Stromal Eosinophilia

Article

Author: Steinberg, Mitchell ; Reddy, Rekha ; Axelrod, Brandon

Traumatic ulcerative granuloma with stromal eosinophilia (TUGSE) is a reactive and chronic ulcerative lesion that is most frequently found on the tongue. It appears as a large yellowish ulcer with elevated margins and central induration. TUGSEs exhibit a characteristic pattern of regression often spontaneously, following incisional biopsy, or after removal of the potential traumatic trigger. Herein, we present an unusual case of a TUGSE on the anterior maxillary gingiva of a 70-year-old male that regressed following incisional biopsy. Histopathologic evaluation revealed fragments of squamous mucosa and submucosal tissue with large atypical cells mixed with small lymphocytes, abundant eosinophils, and focal clusters of plasma cells. Immunohistochemistry was performed and the large, atypical cells were positive for CD3, CD4, CD5, and CD30 and negative for CD1a, CD8, CD20, CD56, CD117, ALK1, Langerin, and EBER ISH. To our knowledge, this is the first case of TUGSE reported in the anterior maxilla.

01 Oct 2024·Journal of Cutaneous Pathology

Coexistence of large cell transformed mycosis fungoides and diffuse large B‐cell lymphoma in one patient

Article

Author: Nikbakht, Neda ; Bhatti, Safiyyah ; Alpdogan, Onder ; Suriano, Jayson ; Holtmeyer, Caleb ; Joffe, Daniel ; Lee, Jason B. ; Talasila, Sahithi ; Tekmen, Volkan ; Rohan, Thomas Z.

AbstractDiffuse large B‐cell lymphoma (DLBCL) is the most common and aggressive subtype of non‐Hodgkin lymphoma. The overall risk of developing DLBCL is increased in patients with other lymphomas, such as mycosis fungoides (MF). In this report, we present an 81‐year‐old female with early‐stage MF who simultaneously progressed to tumor stage, large‐cell transformed (LCT) MF and developed a primary DLBCL in a lymph node (LN). She presented with a tumor on her leg and new lymphadenopathy in her right axilla. Skin biopsy of the tumor revealed infiltration of large atypical CD3+, CD4+, and CD30+ cells, and a smaller portion of CD8+ cells in the dermis, consistent with LCT MF. Biopsy of the axillary LN revealed diffuse sheets of CD20+, BCL‐2+, c‐MYC+, and CD10− cells, highly suggestive of double expressor DLBCL. High‐throughput sequencing revealed monoclonal T cells in the skin tumor and a monoclonal B‐cell population in the LN. The above findings led to simultaneous diagnoses of LCT MF and nodal double expressor DLBCL. Our case demonstrates the importance of performing a full pathological workup in cutaneous T‐cell lymphoma patients presenting with lymphadenopathy.

News (Medical) associated with CD3 x CD30

03 Nov 2022

·www.biospace.com

Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)

Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody®-CD3xCD20) in a variety of treatment settings and hematologic malignancies Four oral presentations highlighting data evaluating epcoritamab for the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL), R/R follicular lymphoma (FL), previously untreated FL, and Richter's syndrome New data evaluating investigational medicines in Genmab’s early portfolio of cancer immunotherapies will also be presented Genmab to host 2022 R&D Update and ASH Data Review meeting December 12 COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) announced today that 19 abstracts evaluating various investigational medicines in its pipeline have been accepted for presentation at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH), being held at the Ernest N. Morial Convention Center in New Orleans, Louisiana, and virtually, December 10-13. The presentations will include four oral and six poster presentations highlighting data from several clinical trials evaluating the safety and efficacy of epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology, alone or in combination for the treatment of patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), R/R follicular lymphoma (FL), previously untreated FL and Richter’s syndrome. Additionally, abstracts evaluating two investigational medicines in Genmab’s early pipeline have been accepted for presentation, including the first-in-human data from the phase 1/2 trial evaluating GEN3014 (HexaBody®-CD38), an investigational novel human CD38 monoclonal antibody, in patients with R/R multiple myeloma (MM). In addition, preclinical data from a novel drug candidate GEN3017 (DuoBody®-CD3xCD30) will also be presented. All abstracts accepted for presentation have been published on the ASH website. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies are committed to evaluating epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of B-cell malignancies, including an ongoing phase 3, open-label, randomized clinical trial evaluating epcoritamab as a monotherapy in patients with relapsed/refractory LBCL, including DLBCL (NCT: 04628494) and a phase 3, open-label randomized clinical trial evaluating epcoritamab in combination in patients with relapsed/refractory follicular lymphoma (FL) (NCT: 05409066). “As part of our commitment to the blood cancer community, we continue to advance our research and innovative technologies in an effort to develop differentiated therapies with the goal of transforming the future of treatment for patients,” said Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab. “The robust data being presented at this year’s American Society of Hematology meeting are encouraging and support the potential of epcoritamab to become a core therapy for B-cell malignancies.” 2022 R&D Update and ASH Data Review On Monday, December 12, at 8:00 PM EST (7:00 PM CST / 1:00 AM GMT), Genmab will host its 2022 R&D Update and ASH Data Review. The event will be conducted and webcast live. Details, including the webcast link and registration can be found here. This meeting is not an official program of the ASH Annual Meeting. Abstracts accepted at ASH: Epcoritamab (DuoBody®-CD3xCD20) Abstract Number Abstract Title Type of Presentation Date/Time of Presentation 348 Subcutaneous Epcoritamab in Patients with Richter’s Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1). Kater et. al. Oral Saturday, December 10, 4:00 PM - 5:30 PM 443 Subcutaneous Epcoritamab + R-DHAX/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results. Abrisqueta et. al. Oral Sunday, December 11, 9:30 AM - 11:00 AM 609 Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update. Falchi et. al. Oral Sunday, December 11, 4:30 PM - 6:00 PM 611 Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial. Falchi et. al. Oral Sunday, December 11, 4:30 PM - 6:00 PM 4251 Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL). Phillips et. al. Poster Monday, December 12, 6:00 PM - 8:00 PM 3580 Improvements in Lymphoma Symptoms and Health-related Quality of Life in Patients with Relapsed or Refractory Large B-cell Lymphoma Treated with Epcoritamab. Phillips et. al. Poster Sunday, December 11, 6:00 PM - 8:00 PM 4912 Indirect Comparison of the Efficacy of Subcutaneous Epcoritamab Dose Expansion (EPCORE NHL-1 Trial) in Patients With Relapsed or Refractory Large B-cell Lymphoma. Salles et. al. Poster Monday, December 12, 6:00 PM - 8:00 PM 2874 Deep peripheral T cell subset immune-profiling in relapse/refractory non-Hodgkins lymphoma (NHL): Evaluation of baseline samples from the Epcoritamab 3013-01 trial. Blum et. al. Poster Sunday, December 11, 6:00 PM - 8:00 PM 2859 Transcriptomic Comparison of Non-Hodgkin Lymphomas in Relapsed/Refractory versus Newly Diagnosed Patients with Single Slides. Jabado et. al. Poster Sunday, December 11, 6:00 PM - 8:00 PM 1663 Phase 1b Trial of Subcutaneous Epcoritamab Among Pediatric Patients With Relapsed or Refractory Aggressive Mature B-Cell Neoplasms. Cairo et. al. Poster Saturday, December 10, 5:30 PM - 7:30 PM 4182 Evaluation of Epcoritamab and Rituximab Combination in Preclinical Models of B-cell non-Hodgkin’s Lymphoma (NHL). Epling-Burnette et. al. Poster Monday, December 12, 6:00 PM - 8:00 PM 4206 Phase 3 Trial of Subcutaneous Epcoritamab in Combination With Rituximab and Lenalidomide (R2) vs R2 Without Epcoritamab Among Patients With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1). Falchi et. al. Poster Monday, December 12, 6:00 PM - 8:00 PM 4271 Phase 2 Trial to Evaluate Safety of Subcutaneous Epcoritamab Monotherapy in the Outpatient Setting Among Patients With Relapsed or Refractory Diffuse Grade 1–3a Large B-Cell and Follicular Lymphoma. Sharman et. al. Poster Monday, December 12, 6:00 PM - 8:00 PM 5524 Assessing Safety, Tolerability, and Efficacy of Subcutaneous Epcoritamab in Novel Combinations with Anti-Neoplastic Agents in Patients with Non-Hodgkin Lymphoma in a Phase 1b/2, Open-Label Study. Sehn et. al. Publication NA GEN3014 (HexaBody®-CD38) Abstract Number Abstract Title Type of Presentation Date/Time of Presentation 3254 Preliminary Dose-Escalation Results From a First-in-Human Phase 1/2 Study of GEN3014 (HexaBody®-CD38) in Patients (pts) With Relapsed or Refractory (R/R) Multiple Myeloma (MM). Spencer et. al. Poster Sunday, December 11 6:00-8:00 PM GEN3017 (DuoBody®-CD3xCD30) Abstract Number Abstract Title Type of Presentation Date/Time of Presentation 1366 DuoBody®-CD3xCD30 shows potent preclinical anti-tumor activity in vitro in CD30+ hematologic malignancies. Oostindie et. al. Poster Sunday, December 11, 6:00 PM - 8:00 PM Real-World Evidence Abstract Number Abstract Title Type of Presentation Date/Time of Presentation 2978 Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated with Standard of Care: a COTA Database Analysis. Ip et. al. Poster Sunday, December 11, 6:00 PM - 8:00 PM 2296 Treatment Patterns and Outcomes in Patients With Follicular Lymphoma Receiving at Least 3 Lines of Therapy: a Real-World Evaluation in the United States. Phillips et. al. Poster Saturday, December 10, 5:30 PM - 7:30 PM 2215 Health Care Resource Utilization and Costs of CAR T Therapy in Patients With Large B-Cell Lymphoma: A Retrospective US Claims Database Analysis. Davies et. al. Poster Saturday, December 10, 5:30 PM - 7:30 PM About Epcoritamab Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response towards target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B-cells and induces T cell mediated killing of CD20+ cells.i CD20 is expressed on B-cells and a clinically validated therapeutic target in many B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia.ii,iii About Genmab Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab’s vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people’s lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab. This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at . Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. _______________________ i Engelberts et al. "DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing." EBioMedicine. 2020;52:102625. DOI: 10.1016/j.ebiom.2019.102625 ii Rafiq, Butchar, Cheney, et al. "Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties." J. Immunol. 2013;190(6):2702-2711. DOI: 10.4049/jimmunol.1202588 iii Singh, Gupta, Almasan. "Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response." J Cancer Sci Ther. 2015;7(11):347-358. DOI: 10.4172/1948-5956.1000373

AntibodyImmunotherapyADCFinancial Statement

28 Sep 2022

·www.prnewswire.com

Bispecific Antibodies for Cancer Market Size to Grow by USD 396.56 million, Emerging Bispecific Antibody Generation Platforms to be Key Trend - Technavio

NEW YORK, Sept. 28, 2022 /PRNewswire/ -- In the bispecific antibodies for cancer market, emerging bispecific antibody generation platforms will be a key trend during the forecast period. For instance, Xencor is developing XmAb20717, XmAb22841, XmAb23104, XmAb24306, and XmAb14045, which are currently in the early phase of development, using the XmAb antibody engineering platform. In addition, Aptevo Therapeutics has developed APVO436 using its ADAPTIR platform for treating patients with acute myeloid leukemia. Therefore, such platforms will drive market growth during the forecast period. Continue Reading Technavio has announced its latest market research report titled Global Bispecific Antibodies for Cancer Market 2022-2026 The bispecific antibodies for cancer market size is expected to grow by USD 396.56 million from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 9.06% during the forecast period, according to Technavio. Our comprehensive report summary includes the market size and forecast along with research methodology. The FREE sample report is available in PDF format The increasing prevalence of cancer is driving the growth of the bispecific antibodies for cancer market growth. However, factors such as the high cost of drugs may challenge the market growth during the forecast period. Bispecific Antibodies For Cancer Market: Type Landscape By type, the market has been segmented into CD19 or CD3 and CD30 or CD16A. The CD19 or CD3 segment will be the largest contributor to market growth during the forecast period. Bispecific antibodies have several advantages when compared to monoclonal antibodies. They can redirect specific immune cells to the site of the tumor cells to boost tumor killing. In addition, they can potentially increase the binding specificity by interacting with two different cell-surface antigens instead of one. They are also able to block two different pathways that exert unique pathogenesis simultaneously. Such advantages will drive the growth of the segment during the forecast period. Bispecific Antibodies For Cancer Market: Geographic Landscape Based on geography, the market has been segmented into North America, Europe, Asia, and Rest of World (ROW). North America is expected to have significant growth during the forecast period. About 39% of the market's overall growth is expected to originate from this region. The US is the key country for the bispecific antibodies for the cancer market in North America. The growth of this region is attributed to factors such as the availability of reimbursement schemes. Moreover, this region is expected to grow at a faster rate than other regions. Find out about the contribution of each region of the market. Buy Now to gain access to country-specific information Companies Covered ABL Bio Inc. AFFIMED N.V. Akeso Inc. Amgen Inc. Aptevo Therapeutics Inc. Astellas Pharma Inc. Chugai Pharmaceutical Co. Ltd. Eli Lilly and Co. EPIMAB BIOTHERAPEUTICS INC. F. Hoffmann La Roche Ltd. F-STAR THERAPEUTICS INC. Glenmark Pharmaceuticals Ltd. Johnson and Johnson Inc. Mereo BioPharma Group Plc Merus N.V. Pfizer Inc. Regeneron Pharmaceuticals Inc. TG Therapeutics Inc. Xencor Inc. Y mAbs Therapeutics Inc. For learning about strategic initiatives used by vendors, as well as key news and the latest developments, View our FREE PDF Sample Report Now What our reports offer Market share assessments for regional-level and country-level segments Strategic recommendations for the new entrants Covers market data for 2021, 2022, until 2026 Market trends (opportunities, drivers, threats, challenges, investment opportunities, and recommendations) Strategic recommendations in key business segments as per the market approximations Competitive landscaping highlighting the common trends Company profiling with detailed strategies, recent developments, and financials Supply chain trends that map the latest technological advances Related Reports Non-melanoma Skin Cancer Market by Type and Geography - Forecast and Analysis 2022-2026: The non-melanoma skin cancer market share is expected to increase by USD 180.97 million from 2021 to 2026. Colorectal Cancer Therapeutics Market by Type and Geography - Forecast and Analysis 2022-2026: The colorectal cancer therapeutics market share is expected to increase by USD 2.45 bn from 2021 to 2026. Browse Health Care Market Reports Table of Contents 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Type Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between 2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Bargaining power of buyers – Impact of key factors in 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Type 5.1 Market segments Exhibit 24: Chart on Type - Market share 2021-2026 (%) Exhibit 25: Data Table on Type - Market share 2021-2026 (%) 5.2 Comparison by Type Exhibit 26: Chart on Comparison by Type Exhibit 27: Data Table on Comparison by Type 5.3 CD19 or CD3 - Market size and forecast 2021-2026 Exhibit 28: Chart on CD19 or CD3 - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on CD19 or CD3 - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on CD19 or CD3 - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on CD19 or CD3 - Year-over-year growth 2021-2026 (%) 5.4 CD30 or CD16A - Market size and forecast 2021-2026 Exhibit 32: Chart on CD30 or CD16A - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on CD30 or CD16A - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on CD30 or CD16A - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on CD30 or CD16A - Year-over-year growth 2021-2026 (%) 5.5 Market opportunity by Type Exhibit 36: Market opportunity by Type ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 38: Chart on Market share by geography 2021-2026 (%) Exhibit 39: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 40: Chart on Geographic comparison Exhibit 41: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 Asia - Market size and forecast 2021-2026 Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 Ireland - Market size and forecast 2021-2026 Exhibit 62: Chart on Ireland - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on Ireland - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on Ireland - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on Ireland - Year-over-year growth 2021-2026 (%) 7.9 China - Market size and forecast 2021-2026 Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%) 7.10 Hungary - Market size and forecast 2021-2026 Exhibit 70: Chart on Hungary - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on Hungary - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on Hungary - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on Hungary - Year-over-year growth 2021-2026 (%) 7.11 India - Market size and forecast 2021-2026 Exhibit 74: Chart on India - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on India - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on India - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on India - Year-over-year growth 2021-2026 (%) 7.12 Market opportunity by geography Exhibit 78: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 79: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 80: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 81: Overview on factors of disruption 9.4 Industry risks Exhibit 82: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 83: Vendors covered 10.2 Market positioning of vendors Exhibit 84: Matrix on vendor position and classification 10.3 ABL Bio Inc. Exhibit 85: ABL Bio Inc. - Overview Exhibit 86: ABL Bio Inc. - Product / Service Exhibit 87: ABL Bio Inc. - Key offerings 10.4 Amgen Inc. Exhibit 88: Amgen Inc. - Overview Exhibit 89: Amgen Inc. - Product / Service Exhibit 90: Amgen Inc. - Key offerings 10.5 Astellas Pharma Inc. Exhibit 91: Astellas Pharma Inc. - Overview Exhibit 92: Astellas Pharma Inc. - Product / Service Exhibit 93: Astellas Pharma Inc. - Key news Exhibit 94: Astellas Pharma Inc. - Key offerings 10.6 Eli Lilly and Co. Exhibit 95: Eli Lilly and Co. - Overview Exhibit 96: Eli Lilly and Co. - Business segments Exhibit 97: Eli Lilly and Co. - Key offerings Exhibit 98: Eli Lilly and Co. - Segment focus 10.7 F. Hoffmann La Roche Ltd. Exhibit 99: F. Hoffmann La Roche Ltd. - Overview Exhibit 100: F. Hoffmann La Roche Ltd. - Business segments Exhibit 101: F. Hoffmann La Roche Ltd. - Key news Exhibit 102: F. Hoffmann La Roche Ltd. - Key offerings Exhibit 103: F. Hoffmann La Roche Ltd. - Segment focus 10.8 Johnson and Johnson Inc. Exhibit 104: Johnson and Johnson Inc. - Overview Exhibit 105: Johnson and Johnson Inc. - Business segments Exhibit 106: Johnson and Johnson Inc. - Key news Exhibit 107: Johnson and Johnson Inc. - Key offerings Exhibit 108: Johnson and Johnson Inc. - Segment focus 10.9 Merus N.V. Exhibit 109: Merus N.V. - Overview Exhibit 110: Merus N.V. - Key offerings 10.10 Pfizer Inc. Exhibit 111: Pfizer Inc. - Overview Exhibit 112: Pfizer Inc. - Product / Service Exhibit 113: Pfizer Inc. - Key news Exhibit 114: Pfizer Inc. - Key offerings 10.11 Regeneron Pharmaceuticals Inc. Exhibit 115: Regeneron Pharmaceuticals Inc. - Overview Exhibit 116: Regeneron Pharmaceuticals Inc. - Product / Service Exhibit 117: Regeneron Pharmaceuticals Inc. - Key offerings 10.12 TG Therapeutics Inc. Exhibit 118: TG Therapeutics Inc. - Overview Exhibit 119: TG Therapeutics Inc. - Product / Service Exhibit 120: TG Therapeutics Inc. - Key offerings 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 121: Inclusions checklist Exhibit 122: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 123: Currency conversion rates for US$ 11.4 Research methodology Exhibit 124: Research methodology Exhibit 125: Validation techniques employed for market sizing Exhibit 126: Information sources 11.5 List of abbreviations Exhibit 127: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

CollaborateAntibody

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis